Related references
Note: Only part of the references are listed.A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)
T. F. Cloughesy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor
Shideng Bao et al.
CANCER RESEARCH (2006)
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
WB Pope et al.
NEUROLOGY (2006)
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study
MD Prados et al.
NEURO-ONCOLOGY (2006)
Dexamethasone normalizes brain tumor hemodynamics as indicated by dynamic susceptibility contrast MRI perfusion parameters
CC Quarles et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2005)
Plasma and cerebrospinal fluid pharmacokineties of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates
SS Jacobs et al.
CLINICAL CANCER RESEARCH (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11
TT Batchelor et al.
NEURO-ONCOLOGY (2004)
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors
RT Tong et al.
CANCER RESEARCH (2004)
MRI monitoring of avastin™ antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer
A Preda et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2004)
Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model
EA Neuwelt et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: Correlation with histopathology
S Cha et al.
MAGNETIC RESONANCE IN MEDICINE (2003)
Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394
SA Grossman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Intra-arterial carboplatin and intravenous etoposide for the treatment of recurrent and progressive non-GBM gliomas
HB Newton et al.
JOURNAL OF NEURO-ONCOLOGY (2002)
Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study
B Jeremic et al.
JOURNAL OF NEURO-ONCOLOGY (2001)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
